Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS

https://doi.org/10.17749/2070-4909.2015.8.4.050-061

Full Text:

Abstract

Aim. Hospital-based economic analysis for the use of thrombopoietin receptor agonists (TRA) Eltrombopag and Romiplostim has been performed in patients with chronic idiopathic thrombocytopenic purpura (ITP) at the background failure of previous treatment options. Materials and methods. Two models for the cost-minimization analysis (model 1) and analysis of the budget impact TRA usage (model 2) are developed on the basis of Microsoft Excel software. The models are based on hypothesis of the difference between the drugs in terms of clinical efficacy and safety and this hypothesis is grounded on the results of randomized controlled trials (RCT) and indirect RCT comparison. The expenditures for drugs of TRA group and for the medical care including the costs for drugs administration, bleeding treatment, "rescue therapy" and follow-up monitoring during treatment are calculated in the mentioned models. The costs of the RF health system have been calculated taking into account the management peculiarities and financing of medical assistance that allows use the models in all regions of Russia. The study was conducted from September to December 2015. The data of state statistical supervision, registered limit transfer drug prices from the list of life-saving and essential medicines (LSEM), the guide price of the manufacturer in the case of application filing for Eltrombopag inclusion to such list, and standards of the financial expenses per medical care volume unit of RF in 2015 are used for calculations. Results. It was shown that Eltrombopag use as compared to Romiplostim is economically expedient in the patients with chronic ITP at the background of previous treatment failure, being not less effective and cheaper alternative that allows reduce the cost of one patient annual therapy by 2.68 mln. rubles. Budget impact analysis evidences that Eltrombopag application can significantly reduce the spending of budgetary funds for the chronic ITP therapy, at least with the same efficacy. Budgetary spending is decreased by 1.68 bln. rubles over 5 years with a gradual increase of Eltrombopag share in purchase of TRA. Conclusion. Despite the comparable efficacy and safety Eltrombopag is economically sound option of chronic ITP treatment as compared to Romiplostim. 

About the Authors

E. A. Pyadushkina
Russian Presidential Academy of National Economy and Public Administration, Address: Vernadskogo prospect, 82-1, Moscow, Russia, 119571, RANEPA IPEI, Laboratory for health technology assessment. Tel.: +7(499)9569528, +7(499)9569529. The National Centre for Technology Assessment in Health Care, Moscow
Russian Federation

research fellow of Laboratory for health technology assessment of Applied economic research Institute of Russian academy of national economy and public administration, research fellow of the Autonomous Non-profit Organization “National Center for Health Technology Assessment”.



M. Yu. Frolov
Volgograd State Medical University of the Ministry of Health Russian Federation, Pavshih borzov pl., 1, Volgograd, Russia, 400131.
Russian Federation

PHD (candidate of medical sciences), assistant professor (FUV module) of Clinical pharmacology and intensive therapy department of Volgograd state medical university.



M. V. Avksentyeva
Russian Presidential Academy of National Economy and Public Administration, Vernadskogo prospect, 82-1, Moscow, Russia, 119571, RANEPA, Centre for health technology assessment. Tel.: +7(499)9569528, +7(499)9569529.
Russian Federation

PhD (doctor of medical sciences), leading research fellow of the Centre for health technology assessment of Applied economic research Institute of the Russian Presidential Academy of National Economy and Public Administration, leading research fellow of Centre for health finance of Research Financial institution of Ministry of Finance and Professor of High school of healthcare administration of the Sechenov First Moscow state medical university.



References

1. Vorob'ev P.A., Krasnova L.S., Borisenko O.V. Klinicheskaya farmakologiya i farmakoekonomika. 2010; 4. URL: http://www.rspor.ru/mods/about_us/ff/ff410_web.pdf. (accessed: 01.10.15).

2. Standard: Health Technology Assessment. General provisions [GOST R 56044-2014GOST: Otsenka meditsinskikh tekhnologii. Obshchie polozheniya. GOST R 56044-2014 (In Russian)].

3. Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Revoleid. Reg. nomer: LRS-010032/09020615. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=1125929&t= (accessed: 01.10.15).

4. Directions for use of the drug for medical use Enpleyt. Reg. number: RL-007 739 / 09-190614 [Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Enpleit. Reg. nomer: LRS-007739/09-190614 (In Russian)] URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=12387&t=. (accessed: 01.10.15).

5. Kovaleva L.G., Safonova T.I., Kolosova E.N., Pustovaya E.I., Ryadnenko A.A. Terapevticheskii arkhiv. 2011; 4: 60-65.

6. Lisukov I.A., Maschan A.A., Shamardina A.V. Chagorova T.V., Davydkin I.L., Sycheva T.M., Zagoskina T.P., Karyagina E.V., Salogub G.N., Savinova M.T., Shelekhova T.V., Kovaleva L.G., Shneider T.V., Unzhekova A.N., Kuznetsova E.E., Shatokhin Yu.V., Ivanova M.O., Vinogradova E.Yu., Volodicheva E.M., Markova I.V., Kanyukova O.V., Abdulkadyrov K.M., Sedlova Yu.A., Osyunikhina S.M., Kaplanov K.D., Tsvetaeva N.V., Akhmadeev A.R., Uspenskaya O.S., Kulagin A.D., Medvedeva N.V., Rumyantsev A.G., Afanas'ev B.V. Onkogematologiya. 2013; 8 (2): 61-69.

7. Melikyan A.L., Pustovaya E.N, Tsvetaeva N.V., Abdulkadyrov K.M., Lisukov I.A., Gritsaev S.V., Golenkov A.K., Davydkin I.L., Pospelova T.I., Ivanova V.L., Shatokhin Yu.V., Savchenko V.G. Gematologiya i transfuziologiya. 2015; 60 (1). URL: http://www.critical.ru/consult/pages/thrombocytopenia.pdf. (accessed: 01.10.15).

8. Melikyan A.L., Pustovaya E.N, Tsvetaeva N.V., Davydkin I.L., Golenkov A.K., Gritsaev S.V., Ivanova V.L., Lisukov I.A., Pospelova T.I., Shatokhin Yu.V. Clinical guidelines for diagnosis and treatment of idiopathic thrombocytopenic purpura (primary immune thrombocytopenia) in adults. Approved at the II Congress of Russian hematologists (April 2014) [Klinicheskie rekomendatsii po diagnostike i lecheniyu idiopaticheskoi trombotsitopenicheskoi purpury (pervichnoi immunnoi trombotsitopenii) u vzroslykh. Utverzhdeny na II Kongresse gematologov Rossii (aprel' 2014 g) (in Russian)]. URL: http://www.minzdravrb.ru/minzdrav/docs/itp.pdf. (accessed: 01.10.15).

9. Resolution of the Government of the Russian Federation on April 26, 2012 N 403 Moscow "On the order of the Federal Register of persons suffering from life-threatening and chronic progressive rare (orphan) diseases that can shorten life expectancy of citizens or their disability and its regional segment" [Postanovlenie Pravitel'stva Rossiiskoi Federatsii ot 26 aprelya 2012 g. N 403 g. Moskva «O poryadke vedeniya Federal'nogo registra lits, stradayushchikh zhizneugrozhayushchimi i khronicheskimi progressiruyushchimi redkimi (orfannymi) zabolevaniyami, privodyashchimi k sokrashcheniyu prodolzhitel'nosti zhizni grazhdan ili ikh invalidnosti, i ego regional'nogo segmenta» (in Russian)].

10. Government Decree of November 28, 2014 N 1273 "On the Program of the state guarantees the free provision of medical care to citizens for 2015 and the planning period of 2016 and 2017" (as amended) [Postanovlenie Pravitel'stva RF ot 28 noyabrya 2014 g. N 1273 «O Programme gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi na 2015 god i na planovyi period 2016 i 2017 godov» (s izmeneniyami i dopolneniyami) (in Russian)].

11. Order of the Health Ministry of the Russian Federation of 21.05.2007 N 344 "On approval of the standard of care for patients with idiopathic thrombocytopenic purpura (with specialized assistance)" [Prikaz Minzdravsotsrazvitiya RF ot 21.05.2007 N 344 «Ob utverzhdenii standarta meditsinskoi pomoshchi bol'nym s idiopaticheskoi trombotsitopenicheskoi purpuroi (pri okazanii spetsializirovannoi pomoshchi)» (in Russian)].

12. Federal State Statistics Service. Operative information. Evaluation of the resident population at January 1, 2015 and the average for 2014 [Federal'naya sluzhba gosudarstvennoi statistiki. Operativnaya informatsiya. Otsenka chislennosti postoyannogo naseleniya na 1 yanvarya 2015 goda i v srednem za 2014 god (in Russian)]. URL: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/#. (accessed: 01.10.15).

13. Federal State Statistics Service. Operative information. Evaluation of the resident population at January 1, 2015 and the average for 2014 [Federal'naya sluzhba gosudarstvennoi statistiki. Operativnaya informatsiya. Raspredelenie naseleniya Rossiiskoi Federatsii po polu i vozrastnym gruppam (na 1 yanvarya 2015g.). URL: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/# (in Russian)]. (accessed: 01.10.15).

14. Federal Law of 21 November 2011. No 323-FZ "On the basis of the health of citizens in the Russian Federation" [Federal'nyi zakon ot 21 noyabrya 2011 g. No 323-FZ «Ob osnovakh okhrany zdorov'ya grazhdan v Rossiiskoi Federatsii» (in Russian)] (accessed: 01.10.15).

15. Allen R., Brainsky, A., Grotzinger, K., Roccia T. A Comment on Boyers et al. Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal. Pharmacoeconomics. 2013; 31 (1): 87-89.

16. Boyers D., Jia X., Jenkinson D., Mowatt G. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics. 2012; 30 (6): 483-95.

17. Cheng G., Saleh M. N., Marcher C., Vasey S., Mayer B., Aivado M., Arning M., Stone N.L., Bussel J. B. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011; 377: 393-402.

18. Feudjo-Tepie M.A., Robinson N.J., Bennett D. Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. Journal of Thrombosis and Haemostasis. 2008; 6 (4): 711-712.

19. Fogarty P.F. Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation. Hematology/oncology clinics of North America. 2009; 23 (6): 1213-1221.

20. Fogarty P.F., Segal J.B. The epidemiology of immune thrombocytopenic purpura. Current opinion in hematology. 2007; 14 (5): 515-519.

21. Kuter D.J., Bussel J.B., Lyons R.M., Pullarkat V., Gernsheimer T.B., Senecal F.M., Aledort L.M., George J.N., Kessler C.M., Sanz M.A., Liebman H.A., Slovick F.T., de Wolf J.T., Bourgeois E., Guthrie T.H. Jr, NewlandA.,WasserJ.S.,HamburgS.I.,GrandeC.,Lefr`ereF.,Lichtin A.E., Tarantino M.D., Terebelo H.R., Viallard J.F., Cuevas F.J., Go R.S., Henry D.H., Redner R.L., Rice L., Schipperus M.R., Guo D.M., Nichol J.L. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet. 2008; 371 (9610): 395-403.

22. Mauskopf J.A., Sullivan S.D., Annemans L., Caro J., Mullins C.D., Nuijten M., Orlewska E., Watkins J., Trueman P. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices – budget impact analysis. Value in health. 2007; 10 (5): 336-347.

23. National Institute for Clinical Excellence (NICE). NICE technology appraisal TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura – Costing template. URL: http:// www.nice.org.uk/resource/ta221/html/p/ta221-thrombocytopenicpurpura-romiplostim-costing-template?id=43356mq3pjhrhxncwqdykxuzqe (accessed: 01.10.15).

24. National Institute for Clinical Excellence (NICE). NICE technology appraisal. Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) (TA293). URL: http://www.nice.org.uk/guidance/ta293. (accessed: 01.10.15).

25. National Institute for Clinical Excellence (NICE). NICE technology appraisal. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA205). URL: http://www.nice.org.uk/guidance/ta205 (accessed: 01.10.15).

26. National Institute for Clinical Excellence (NICE). NICE technology appraisal TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) – Costing statement. URL: http://www.nice.org.uk/resource/ta293/html/p/ta293-thrombocytopenic-purpura-eltrombopag-costing-statement?id=mthd7nqxyapjjqw2c5rfmkayim (accessed: 01.10.15).

27. Provan D., Stasi R., Newland A.C., Blanchette V.S., BoltonMaggs P., Bussel J.B., Chong B.H., Clines D.B., Gernsheimer T., Grainger J. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115: 168-186.

28. Saleh M.N., Bussel J.B., Cheng G., Meyer O., Bailey C.K., Arning M., Brainsky A. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, openlabel EXTEND study. Blood. 2013; 121 (3): 537-545.

29. Thomas D.R. Anemia and Quality of Life: Association with Diagnosis and Treatment of Anemias. Handbook of Disease Burdens and Quality of Life Measures. Springer New York. 2010; 1881-1893.


For citation:


Pyadushkina E.A., Frolov M.Y., Avksentyeva M.V. CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2015;8(4):50-61. (In Russ.) https://doi.org/10.17749/2070-4909.2015.8.4.050-061

Views: 1130


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)